期刊文献+

局部进展期胃癌根治术后同期单纯化疗与放化疗的比较研究 被引量:2

下载PDF
导出
摘要 目的比较胃癌根治术后同期单纯化疗与放化疗的疗效。方法将96例患者随机分成两组,即放疗组和单纯化疗组。放化疗组给予三维适形放疗后2周行FOLFOX4方案巩固化疗4-6周,而单纯化疗组只采用FOLFOX4方案化疗6-8周;化疗的同时给予卡培他滨口服,同期患者给予胃黏膜保护剂、抑酸药物和营养支持治疗。结果放化疗组1、2、3年局部控制率和生存率分别为100%、96%、93%和98%、84%、80%,单纯化疗组局部控制率和生存率分别为94%、85%、72%和92%、77%、62%。放化疗组和单纯化疗组均有不同程度的恶心呕吐和白细胞下降,≥3级的白细胞下降发生率分别为22%和15%,≥3级的胃肠道反应率为17%和11%。结论局部进展期胃癌根治术与同步放化疗相比,单纯化疗能够显著提高患者局部控制率和生存率,而且不良反应相对不明显。
出处 《中国医学工程》 2013年第3期48-48,51,共2页 China Medical Engineering
  • 相关文献

参考文献3

  • 1PaoIetti X,Oba K,Burzykowaki T,etal.Chemoradiotherapy as adjuvant treatment of gastric cancer;a meta-analysis[J]. JAMA,2010,303:1792-1737.
  • 2Macdonald JS,Smally SR,Benedetti J,et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[Ji.N J Med,2001,345:725-730.
  • 3王鑫,金晶.局部晚期胃癌术后同步放化疗研究进展[J].实用肿瘤杂志,2011,26(3):225-228. 被引量:7

二级参考文献12

  • 1Parkin D, Pisani P, Ferley J, et al. Global cancer statistics [ J ]. Ca Cancer J Clin, 1999,49 (3) :33 - 64.
  • 2Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis [ J ]. Cancer,2000,88 (4) :921 -932.
  • 3Naveenraj L. Solomon, Michael C. Cheung, Margaret M. Byrne, et al. Does Chemoradiotherapy Improve Outcomes for Surgically Resected Adenocarcinoma of the Stomach or Esophagus [ J ] ? Ann Surg Oncol, 2010, 17 ( 1 ) : 98 - 108.
  • 4MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenoeareinoma of the stomach or gastroesophageal junction [ J]. N Engl J Med, 2001,345 (10) :725 -730.
  • 5Kozak KR, Moody JS: The survival impact of the intergroup 0116 trial on patients with gastric cancer [ J]. Int J Radiat Oncol Biol Phys ,2008,72 (2) :517 -521.
  • 6Natalie G. Cobum, Ulrich Culler, et al : adjuvant therapy for resected gastric cancer-rapid, yet incomplete adoption following results of intergroup 0116 trial [ J]. Int J Radiat Oneol Biol Phys,2008,70(4) :1073 -1080.
  • 7Kim S, Limdo H, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach [ J ]. Int J Radiat Oncol Biol Phys ,2005,63 : 1279 - 1285.
  • 8Lee J, Kang W, Lira D, et al. Phase III trial of adjuvant capecitabine/cisplatin (XP) compared with capecitabine/ cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection ( ARTIST trial) : Safety analysis. 2009 ASCO Annual Meeting [J]. J Clin Oncol,2009,27:15s.
  • 9Jansen EPM, Boot H, Dubbelman R, et al. Postoperative chemoradiotherapy in gastric cancer-a phase I/II dosefinding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy [ J ]. Br J Cancer,2007,97 (6) :712 - 716.
  • 10Edwin PMJ, Boot H, Saunders MP, et al. A phase I - II study of postoperative capecitabine-based chemoradio-therapy in gastric cancer [ J ]. Int J Radiat Oncol Biol Phys,2007,69 ( 5 ) : 1424 - 1428.

共引文献6

同被引文献12

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部